Project Helix Bio is focused on venture creation as the key to transforming the Israeli biotech ecosystem. By systematically building and scaling new biotech companies, we aim to bridge the critical funding and operational gap between academic research and clinical application.Our mission is to turn breakthrough science into impactful ventures by empowering exceptional founders, fostering strategic global partnerships, and providing hands-on support from inception to growth. Through this model, we seek to establish Israel as a global hub for biotech innovation. Over the next decade, we aim to launch 3–5 high-impact biotech companies that will not only advance healthcare but also serve as foundational pillars for a thriving, self-sustaining biotech ecosystem in Israel.

The Biohub is a bi-national initiative designed to accelerate the growth of Israeli HealthTech ventures and deepen their engagement with the US market. At its core, the Biohub views talent as a strategic catalyst, recognizing that strong leadership and companies go hand in hand. To support this, it offers two complementary tracks: a scalable program for enhancing the capabilities of existing executives and a high-touch cohort focused on cultivating emerging leadership. Operating across Israel and the US, the Biohub will identify and support promising ventures with market potential, build operational readiness in Israel, and in the US focus on leadership development and strategic board building with seasoned American executives. By nurturing companies and talent, the Biohub aims to position Israeli ventures for sustainable growth, stronger leadership, and meaningful engagement with the US market.

This initiative explores strategic opportunities for Israel to address critical global customer needs and goals in healthcare, thereby potentially enhancing its attractiveness to leading payers, providers, and multinational corporations (MNCs). By clearly identifying Israel's competitive advantages in that context, it seeks to strengthen and expand collaborations between prominent U.S. healthcare enterprises and the dynamic Israeli innovation ecosystem.

The Israel Translational Science Institute (ITSI) will serve as a national platform to bridge the gap between academic discovery and clinical and real-world application. ITSI will empower researchers to focus on high-risk, building scalable national platforms and projects that harness Israel’s unique capabilities, such as unique technologies and data-science driven approaches (avoiding duplicating other global efforts).

US NW aims to build a strategically engaged US-Israel HealthTech network of ~100 US members by 2030, grounded in high-value relationships and shared opportunities for cross-border commercialization. The initiative focuses on structured growth through annual cohort selection, geographic and sector-based events, and a clear onboarding and engagement model. It will offer layered participation levels, integrate members into startup mentorship, and operate with strong strategic and operational support from 8400.

Accelerate the commercialization and market success of HealthTech and MedTech innovations through structured, targeted programs, executive training, and the establishment of strategic resources. MedTech Commercialization Institute employs a three-tiered approach to accelerate HealthTech commercialization.

• Tier 1 – MCI 1.0: A focused, blueprint-driven, three-month boot camp for early-stage startups (~50 companies/year).

• Tier 2 – MCI 2.0: Tailored global support for companies in or near commercialization (~20 companies/year), addressing the six critical essential for commercial success, including direct international market access and advanced mentoring.

• Tier 3 – Executive Training: Specialized CEO education to build strong leadership for long-term growth.